Eli Lilly's IL-17A inhibitor Taltz is better than 7 biologics in treating plaque psoriasis (PsO)!

News on April 25, 2021 // - Eli Lilly (Eli Lilly) recently in the American Academy of Dermatology 2021 Virtual Conference on experience (AAD VMX) published new evidence that anti-inflammatory drugs Taltz (ixekizumab) treatment of plaque psoriasis
.
Through clinical trial meta-analysis (Meta-analysis) and real world evidence (Real World Evidence, RWE), in the treatment of adult patients with moderate to severe plaque psoriasis, Taltz has shown that compared with other biological agents in terms of key treatment results Greater success
.

In the first one-year network meta-analysis, based on the area under the curve and measured by the Psoriasis Area and Severity Index (PASI) of 100, compared with the other seven biological agents, Taltz treatment showed that the skin lesions were completely removed for one year To produce greater cumulative benefits
.
In addition, in three real analyses of US claims data for 1-3 years, compared with other biological agents studied, patients who received Taltz treatment had longer adherence to treatment, and stronger compliance with prescriptions.
The number of days of monotherapy is longer
.

Lotus Mallbris, M.
D.
, Vice President of Immunology Development at Eli Lilly , said: “We are pleased to introduce our new analysis of clinical trial data, which shows that Taltz provides more for adult patients with psoriasis than the other 7 biological therapies.
The cumulative number of days for complete skin lesion removal
.
This analysis further confirms the results of our clinical trials .
Previous results indicate that Taltz treatment provides rapid and lasting psoriasis improvement
.
We are happy to provide dermatologists with more information about Taltz Insights to help them make important treatment decisions for patients seeking complete removal of skin lesions
.
At Eli Lilly , it’s also important that our research goes beyond controlled clinical trials and incorporates real-world data analysis to provide dermatologists with Clear information on how patients manage psoriasis and respond to treatments in their daily lives
.
"

psoriasis

During the one-year treatment period, Taltz provided the patient with the longest duration of complete removal of the skin lesions:

In a network meta-analysis evaluating the cumulative clinical benefits of biologics for psoriasis, PASI 100 was used to measure the early and sustained effects of biologic drugs approved for psoriasis within one year
.
The data shows that it is compatible with adalimumab (adalimumab, TNF inhibitor), brodalumab (badalumab, IL-17R inhibitor), etanercept (etanercept, TNF inhibitor), guselkumab (gusekuumab) , IL-23 inhibitor), risankizumab (IL-23 inhibitor), secukinumab (skukuzumab, IL-17A inhibitor), ustekinumab (ustekinumab, IL-12/23 inhibitor) , Taltz provides the longest cumulative number of days for patients with psoriasis to completely clear the skin
.
In this analysis, compared with the other seven biological agents, Taltz provided 1-18 weeks longer days for complete skin lesion removal during the one-year treatment period
.

Taltz provided patients with a total of 159 days (95% CI: 147.
4-170.
0 days) or 23 weeks of complete skin removal (PASI 100), which means that patients have completely clean skin about 44% of the year.
The other 7 biological agents are: risankizumab (152 days [141.
6-162.
0 days], or 22 weeks, 42% throughout the year), brodalumab (138 days [119.
0-157.
2 days], 20 weeks, 38% throughout the year); guselkumab (131 days, [120.
8-141.
6 days], 19 weeks, 36% of the year), secukinumab (119 days [111.
7-127.
0 days], or 17 weeks, 33% of the year); ustekinumab (74 days [63.
3-84.
4 Days], or 11 weeks, 20% throughout the year), adalimumab (67 days [55.
7-77.
9 days], or 10 weeks, 18% throughout the year), etanercept (32 days [23.
7-39.
7 days], or 5 weeks, full 9% per year)
.

The lead author of the analysis, MarkG, head of the Department of Clinical Therapeutics, Icahn School of Medicine, Mount Sinai
.
Dr.
Lebwohl, MD, said: “As a dermatologist, I am very pleased to gain insight into the cumulative clinical benefits of biologic therapy for psoriasis in one year
.
When discussing treatment goals, for many patients, the lasting is the top priority.
The
analysis showed that patients who received Taltz treatment for one year had complete removal of skin lesions in approximately 160 days, which is more than any other biological agents included in this analysis
.
"

Taltz is a new type of anti-inflammatory drug developed by Eli Lilly .
The drug is a monoclonal antibody that is administered by subcutaneous injection and can selectively bind to the cytokine interleukin 17A (IL-17A) and inhibit its interaction with IL-17.
The interaction of the body does not bind to the cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F
.
IL-17A is a naturally occurring cytokine involved in normal inflammation and immune response
.
Taltz can inhibit the release of pro-inflammatory cytokines and chemokines
.

In the United States, Taltz was approved for the first time in March 2016, becoming the second IL-17A monoclonal antibody marketed in the United States after Novartis' blockbuster anti-inflammatory drug Cosentyx (secukinumab) .
So far, Taltz has received 5 approvals: (1) for the treatment of moderate to severe plaque psoriasis (PsO) adult patients suitable for systemic therapy or phototherapy; (2) for the treatment of active psoriatic joints (3) for the treatment of active ankylosing spondylitis (AS, also known as radiation axial spondyloarthritis [r-axSpA]) adult patients; (4) for the treatment of suitable systemic treatment Or phototherapy for pediatric patients with moderate to severe plaque psoriasis (6 years old to under 18 years old); (5) For the treatment of active non-radiological axial spondyloarthritis with objective signs of inflammation (nr-axSpA ) Adult patients .

In 2020, Taltz's sales reached 1.
788 billion US dollars, an increase of 33% over the previous year
.
The industry is very optimistic about Taltz's business prospects.
The pharmaceutical market research organization Evaluate previously issued a report predicting that Taltz's sales in 2024 will reach 2.
707 billion US dollars
.
()

Original Source: Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis